Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Exploiting beneficial alloreactive T cells.

L D Barber1, J A Madrigal

  • 1The Anthony Nolan Research Institute, Royal Free Hospital, Pond Street, Hampstead, London, UK. l.barber@medsch.ucl.ac.uk

Vox Sanguinis
|June 8, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High-resolution HLA allele and haplotype frequencies in majority and minority populations of Costa Rica and Nicaragua: Differential admixture proportions in neighboring countries.

HLA·2018
Same author

Single molecule real-time DNA sequencing of HLA genes at ultra-high resolution from 126 International HLA and Immunogenetics Workshop cell lines.

HLA·2017
Same author

Recipient/donor HLA and CMV matching in recipients of T-cell-depleted unrelated donor haematopoietic cell transplants.

Bone marrow transplantation·2017
Same author

Variations in practice in UK transplant centers: results of a related donor care survey.

Bone marrow transplantation·2016
Same author

[Treatment of umbilical cord blood units with interleukin-15 improves hematopoietic stem cell engraftment].

Cirugia y cirujanos·2016
Same author

Further diversity of the 5' promoter region of the MHC class I-related chain B gene.

International journal of immunogenetics·2015
Same journal

Barriers and enablers to non-remunerated plasma donation: A meta-synthesis of the qualitative literature using the theoretical domains framework.

Vox sanguinis·2026
Same journal

Haemolytic disease of the foetus and newborn due to anti-M: A systematic review.

Vox sanguinis·2026
Same journal

In vitro evaluation of apheresis platelet and plasma products collected and stored in non-DEHP disposable sets.

Vox sanguinis·2026
Same journal

Survey of national and regional rare donor programmes regarding Immunoglobulin A deficiency.

Vox sanguinis·2026
Same journal

Fibrinogen recovery in cryoprecipitate prepared from thawed plasma stored for 5 days post-thaw.

Vox sanguinis·2026
Same journal

Abstracts of the 39th International Congress of the ISBT, Kuala Lumpur, Malaysia, 20-24 June 2026.

Vox sanguinis·2026
See all related articles

Beneficial alloreactive T cells can target tumors and promote transplant tolerance. Understanding their molecular basis allows for their isolation and manipulation for cancer immunotherapy and improved transplant outcomes.

Area of Science:

  • Immunology
  • Transplantation immunology
  • Cancer immunotherapy

Background:

  • T-cell responses to allogeneic cells typically cause transplant rejection and graft-vs-host disease.
  • However, alloreactive T cells also possess beneficial functions, including tumor antigen recognition and promotion of transplant tolerance.

Purpose of the Study:

  • To review the identification, isolation, and manipulation of beneficial alloreactive T cells.
  • To explore the exploitation of alloaggression for immunotherapy.

Main Methods:

  • Review of current understanding of the molecular basis of T-cell alloresponses.
  • Analysis of strategies for isolating and manipulating beneficial alloreactive T cell populations.

Main Results:

Related Experiment Videos

  • Significant advancements have been made in understanding the molecular mechanisms underlying T-cell alloreactivity.
  • Identification and isolation of specific alloreactive T cell subsets with therapeutic potential are increasingly feasible.

Conclusions:

  • Separating beneficial from detrimental alloreactive T cells is crucial for advancing transplantation and cancer immunotherapy.
  • Exploiting alloaggression offers promising avenues for developing novel immunotherapeutic strategies.